DURHAM, N.C.–(BUSINESS WIRE)–December 9, 2020 — Mycovia Pharmaceuticals, Inc. (“Mycovia”),
Moscow announces advanced trials for new COVID-19 vaccine
The mayor of Moscow invited residents Wednesday to join trials
Oops! Ben Feldman Accidentally Announces Wife Gave Birth to Baby No. 2
Loose lips! Ben Feldman accidentally revealed that he and his
MediciNova Announces Plans to Move Forward with a Phase 3 Trial of MN-166 (ibudilast) in ALS
LA JOLLA, Calif., April 15, 2019 (GLOBE NEWSWIRE) — MediciNova,
CymaBay Therapeutics Announces Seladelpar Granted Breakthrough Therapy Designation by the FDA for the Treatment of Primary Biliary Cholangitis
NEWARK, Calif., Feb. 15, 2019 (GLOBE NEWSWIRE) — CymaBay Therapeutics,
Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma
ALAMEDA, Calif.–(BUSINESS WIRE)–Jan. 14, 2019– Exelixis, Inc. (NASDAQ:EXEL) today announced
Menlo Therapeutics Announces Results from a Phase 2 Clinical Trial of Serlopitant for the Treatment of Refractory Chronic Cough
REDWOOD CITY, Calif., Oct. 08, 2018 (GLOBE NEWSWIRE) — Menlo
Developed immune therapy against cancer: Nobel prize in medicine in 2018 goes to Allison and Honjo
The Karolinska Institute in Stockholm announced the winners of the
Orphazyme Announces Enrollment of First Patient in Phase III Clinical Trial of Arimoclomol for ALS
Copenhagen, August 10, 2018 – Orphazyme A/S, a biopharmaceutical company
Vaxart Announces Publication of the Phase 1 Results of its Oral Norovirus Tablet Vaccine in Journal of Clinical Investigation Insight
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE) July 12, 2018 –Vaxart, Inc.